Skip to main content
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Main navigation - Mobile
7. Merck & Co.
Opdivo, Novartis Korea, GSK and more—FiercePharmaAsia
Friday, August 24, 2018
Opdivo is priced in China at half its U.S. cost; Novartis names new chief for scandal-hit Korea unit; GSK's Indian consumer unit attracts new buyers.
Eisai, Merck take on Bayer with Lenvima liver cancer nod
Friday, August 17, 2018
Eisai and Merck’s fast-growing Lenvima has got a brand-new market—and Bayer’s Nexavar now has some company in liver cancer.
FiercePharmaAsia—Lenvima, China’s drug invite, Samsung and more
Friday, August 10, 2018
Lenvima's quarterly sales grow to $106 million; China makes 48-drug list for streamlined review; Samsung commits further investment in biologics.
Eisai's Lenvima posts big growth as Merck collab revs up
Friday, August 3, 2018
Merck & Co. likely expected big numbers when it agreed to fork over $5.8 billion to share rights to Eisai's Lenvima. And those numbers are rolling in.
Merck's new partners hone plans for marketing onslaught
Monday, June 4, 2018
Merck spent on-stage ASCO time with new Keytruda data, but behind the scenes, it huddled with teams from its big new partners, AstraZeneca and Eisai.
FiercePharmaAsia—Takeda, WuXi AppTec and more
Friday, June 1, 2018
Takeda investors voice concerns over Shire deal; WuXi AppTec becomes the largest-cap CRO; two families' wealth swells on Gardasil nods.
FDA stalls Eisai and new partner Merck to widen Lenvima's reach
Friday, May 25, 2018
Merck expected big things from Lenvima when it agreed to drop billions on a 50% stake. But in the first expansion bid since that deal, it hit a snag.
FiercePharmaAsia—Merck-Eisai, JW Therapeutics, novel HIV med
Friday, March 9, 2018
Merck gets half of Lenvima's sales in $5.8 billion deal; Juno and WuXi's CAR-T JV got $90 million; FDA approved Taiwanese firm's HIV drug.
Merck lays out up to $5.8B for half of Eisai's Lenvima
Thursday, March 8, 2018
Less than eight months after nabbing a 50% share of hot AstraZeneca drug Lynparza, Merck is back with another partnership—this time on Eisai’s Lenvima.